5-Iodotubercidin: A Novel Anti-Tuberculosis Lead with Promising Antimicrobial Activity, Pharmacokinetics, and Safety Profile.

AIMS Tuberculosis (TB) remains a major global health threat, underscoring the urgent need for novel therapeutics. 5-Iodotubercidin (5-ITu), a purine-based protein kinase inhibitor, has not been previously evaluated for anti-tuberculosis (anti-TB) applications. METHODS AND RESULTS This study presents the first comprehensive characterization of 5-ITu as a lead compound for TB treatment, focusing on its antimicrobial activity, pharmacokinetic (PK) properties and safety profile. 5-ITu exhibited notable antimicrobial activity against Mycobacterium tuberculosis (MTB) standard strain H37Rv and 25 multidrug-resistant (MDR) clinical isolates, with MIC values ranging from 0.23 to 0.9 µg mL-1, while showing MIC values >32 µg mL-1 against eight other bacterial strains. Checkerboard assays revealed synergy with multiple anti-TB drugs against clinical MDR isolates. The permeabilizing effect of 5-ITu on the bacterial inner membrane, along with the associated dissipation of membrane potential and reduction of intracellular ATP, was confirmed by membrane integrity and function assays. PK study in mice following oral administration of 10 mg kg-1 showed rapid absorption, high plasma exposure, and an atypical plateau during the elimination phase. Cytotoxicity assays and acute toxicity studies in mice revealed moderate toxicity of 5-ITu toward mammalian cells and rodents. CONCLUSIONS Despite its moderate toxicity, the promising anti-TB activity and favorable PK profile of 5-ITu support its potential as a lead compound for structural optimization in anti-TB drug development.

• Publication year

  2025

• Venue

  Journal of Applied Microbiology

• Publication date

  2025-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jambio/lxaf257PMID 41092290
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon

  2025cited by this paper
• Adenosine Kinase: An Epigenetic Modulator and Drug Target

  2025cited by this paper
• Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity

  2025cited by this paper
• Clinical research progress of novel antituberculosis drugs on multidrug-resistant tuberculosis.

  2024cited by this paper
• A randomised crossover design study comparing the pharmacokinetics and pharmacodynamics of two single doses of oral Aspirin (75 mg v 150mg) in pregnant women at risk of pre-eclampsia (DORA): A Response.

  2024cited by this paper
• Assessment of the Efficacy of the Antihistamine Drug Rupatadine Used Alone or in Combination against Mycobacteria

  2024cited by this paper
• Tuberculosis treatment-shortening.

  2024cited by this paper
• 5-Iodotubercidin Inhibits the Growth of Insulinoma Cells by Inducing Apoptosis

  2023cited by this paper
• Utilization of Existing Human Kinase Inhibitors as Scaffolds in the Development of New Antimicrobials

  2023cited by this paper
• Recent advances in the treatment of tuberculosis.

  2023cited by this paper
• Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets

  2023cited by this paper
• Clofazimine for the treatment of tuberculosis

  2023cited by this paper
• 5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis

  2022cited by this paper
• Isobavachalcone From Cullen corylifolium Presents Significant Antibacterial Activity Against Clostridium difficile Through Disruption of the Cell Membrane

  2022cited by this paper
• Analogues of Pyrimidine Nucleosides as Mycobacteria Growth Inhibitors

  2022cited by this paper
• Synergistic antibacterial activity of tetrandrine combined with colistin against MCR-mediated colistin-resistant Salmonella.

  2022cited by this paper
• Intestinal Excretion, Intestinal Recirculation, and Renal Tubule Reabsorption Are Underappreciated Mechanisms That Drive the Distribution and Pharmacokinetic Behavior of Small Molecule Drugs.

  2021cited by this paper
• A broad-spectrum antibiotic adjuvant reverses multidrug-resistant Gram-negative pathogens

  2020cited by this paper
• Metformin Restores Tetracyclines Susceptibility against Multidrug Resistant Bacteria

  2020cited by this paper
• Adenosine Kinase: A Key Regulator of Purinergic Physiology.

  2020cited by this paper
• Therapeutic potential of adenosine kinase inhibition—Revisited

  2019cited by this paper
• Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines.

  2019cited by this paper
• Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase

  2019cited by this paper
• In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis

  2019cited by this paper
• 5′-Iodotubercidin represses insulinoma-associated-1 expression, decreases cAMP levels, and suppresses human neuroblastoma cell growth

  2019cited by this paper
• Conformationally Constrained Cinnolinone Nucleoside Analogues as Siderophore Biosynthesis Inhibitors for Tuberculosis.

  2018cited by this paper
• Synthesis of a 3′-C-ethynyl-β-d-ribofuranose purine nucleoside library: Discovery of C7-deazapurine analogs as potent antiproliferative nucleosides

  2018cited by this paper
• Inhibitory effect of 5-iodotubercidin on pigmentation.

  2017cited by this paper
• South (S)- and North (N)-Methanocarba-7-Deazaadenosine Analogues as Inhibitors of Human Adenosine Kinase.

  2016cited by this paper
• Latent Mycobacterium tuberculosis infection.

  2015cited by this paper
• Nucleoside analogs and tuberculosis: new weapons against an old enemy.

  2015cited by this paper
• Synthesis, cytostatic, antimicrobial, and anti-HCV activity of 6-substituted 7-(het)aryl-7-deazapurine ribonucleosides.

  2014cited by this paper
• Identification of 5-Iodotubercidin as a Genotoxic Drug with Anti-Cancer Potential

  2013cited by this paper
• Non-compartmental analysis.

  2012cited by this paper
• Mycobacterium tuberculosis Pathogenesis and Molecular Determinants of Virulence

  2003cited by this paper
• 5-Iodotubercidin and proglycosyn: a comparison of two glycogenic compounds in hepatocytes from fasted rats.

  1996cited by this paper
• Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor.

  1994cited by this paper
• Stimulation of rat liver glycogen synthesis by the adenosine kinase inhibitor 5-iodotubercidin.

  1993cited by this paper
• Analytical strategies for therapeutic monitoring of drugs in biological fluids.

  1985cited by this paper

• No citing papers are available for this paper.